{
    "id": 28513,
    "fullName": "EGFR D770_P772dup",
    "impact": "duplication",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR D770_P772dup (also referred to as P772_H773insDNP or V769_D770insDNP) indicates the insertion of 3 duplicate amino acids, aspartic acid (D)-770 through proline (P)-772, in the protein kinase domain of the Egfr protein (UniProt.org). D770_P772dup has not been biochemically characterized, but is predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",
            "references": [
                {
                    "id": 440,
                    "pubMedId": 24353160,
                    "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "D770_P772dup",
    "createDate": "07/25/2018",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 177002,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181325_55181326insGACAACCCT",
        "cDna": "c.2316_2317insGACAACCCT",
        "protein": "p.D770_P772dupDNP",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14840,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR D770_P772dup (reported as P772_H773insDNP) (PMID: 29686424; NCT03066206).",
            "molecularProfile": {
                "id": 30378,
                "profileName": "EGFR D770_P772dup"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15399,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 patient harboring EGFR D770_P772dup achieved partial response (PMID: 30351341; NCT01854034).",
            "molecularProfile": {
                "id": 30378,
                "profileName": "EGFR D770_P772dup"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13126,
                    "pubMedId": 30351341,
                    "title": "Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30351341"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30378,
            "profileName": "EGFR D770_P772dup",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 177002,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181325_55181326insGACAACCCT",
            "cDna": "c.2316_2317insGACAACCCT",
            "protein": "p.D770_P772dupDNP",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}